Volume 20, Issue 2

Translations (pdf): Spanish  |  French  |  Portuguese

Stephaun E. Wallace, PhD, Editor-in-Chief
Stephaun E. Wallace, PhD, Editor-in-Chief

Welcome to the latest edition of the HIV Vaccine Trials Network (HVTN) Community Compass.

In this issue, we highlight some of the efforts of our clinical trial sites and updates from the HVTN Leadership and Operations Center (Core), including a special article that describes how and why the Network and other collaborators have pivoted our attention to respond to COVID-19. The COVID-19 Prevention Network (CoVPN) has been organized at the direction of Dr. Anthony Fauci, leveraging the clinical trials, laboratory, community engagement, and statistical/data management expertise of key NIAID clinical trials networks to test vaccines and monoclonal antibodies that are designed to protect people from COVID-19 disease. For more information on the CoVPN and to learn more about the clinical trials, visit www.PreventCOVID.org. Though we have pivoted our efforts in response to COVID-19, we at the HVTN remain committed to our pursuit to find safe and effective preventive HIV vaccines that have global application.

I believe we will see an end to the COVID-19 pandemic, but we cannot achieve this end ethically by leaving anyone behind, or without ensuring that appropriate efforts are focused on those who are most vulnerable. There are many stakeholder mobilization efforts happening in local and national settings around the world with goals of raising awareness about these issues, and ensuring resources and solutions are inclusive of those most impacted and vulnerable. We are a global community; let us work together in response to this pandemic.

The Mosaico Study, also known as HVTN 706/HPX 3002, was previously paused in response to COVID-19. The study team wanted to ensure the safety and health of participants and study staff. We are in the process of working with regulatory groups and clinical trial sites to ensure a safe restart to the study globally. Our other HIV vaccine and antibody concept proposals and protocols are starting to reopen now.

Change is said to be the only constant in our lives. 2020 has brought about significant change to me personally and professionally, to my colleagues and our community partners, and I am certain to all of you. One of the significant changes that we touch on in this issue is the retirement of our very own Steven Wakefield (who prefers to go by just “Wakefield”) in July 2020. Wakefield was not only one of the initial hires of the HVTN, but has helped to lead and fortify community engagement within the network, and in communities globally.

Please help us ensure that this publication is representative of our entire global HVTN community! HVTN members (who have access to the HVTN member's website) can use our submission page that offers the ability to submit content and articles for inclusion in future issues. 

Thank you for your continued support of the HVTN wherever you are in the world, for the work that you do in whatever role you have in the HVTN community, and for the impact we have been able to make in our collective history and communities, together. Though we have come very far in response to the HIV epidemic, we have so much further to go to achieve a globally effective HIV vaccine. The HVTN Community Compass team wants to be everywhere you are, so please share with us what's happening at your research sites, institutions, and in your communities, so that we can share it with the world.

Be well,

Stephaun E. Wallace, PhD

Editor-in-Chief, HVTN Community Compass